Neuvivo, a California-based biopharmaceutical company developing breakthrough novel therapies for Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative diseases, announced on Thursday the appointment of Mark Henderson, PhD as vice president of Manufacturing.

In this role Dr Henderson will oversee manufacturing, quality assurance and drug formulation, including for NP001, the company's investigational treatment for ALS.

NP001 has been granted Orphan Drug and Fast Track Designations by the US Food and Drug Administration (FDA).

Dr Henderson has more than 25 years of experience in pharmaceutical facility operations, quality assurance and manufacturing. He has worked with global biotechnology companies and a private, clinical-stage startup, holding leadership roles in early-stage manufacturing and process development for well-established groups as well as building teams from the ground up.